Alamar Biosciences

ALMR · Nasdaq Filing snapshot

Alamar Biosciences develops ultra-sensitive proteomics tools built on its NULISA platform, with the ARGO HT System and assay panels measuring low-abundance protein biomarkers from biofluids for translational research and, eventually, clinical diagnostics. Revenue grew 195% to $74.2M. Its $17.00 Nasdaq IPO raised about $191M gross. The filing names its primary competitors as Olink — now owned by Thermo Fisher — and Quanterix, both offering high-sensitivity immunoassays and affinity-based or mass-spectrometry protein detection.

Listed

Apr 17, 2026

Raised

$191M

Sector

Life-Science Tools · Proteomics · Diagnostics

Named rivals

2 in the S-1

Named in the S-1 2 named

Alamar Biosciences

ALMR · the filer

Olink

named 24×

Quanterix

named 4×

“

The read

Its NULISA platform and ARGO instruments take on just two named rivals in ultra-sensitive proteomics — Olink (now owned by Thermo Fisher), referenced 24 times, and Quanterix. Revenue tripled to $74.2M, up 195%.

Want the full picture on Alamar Biosciences?

Request the deep Exposure Report — share-of-presence, a 90-day signal timeline, and the white space these 2 rivals leave open. We build it within 48 hours.

Request full coverage